Conclusion: Final Thoughts on Managing Hodgkin Lymphoma


For High-Definition, Click

In the final segment, moderator Peter L. Salgo, MD, asks panelists Jonathan W. Friedberg, MD, Paul A. Hamlin, MD, Craig Moskowitz, MD, and Lauren C. Pinter-Brown, MD, to provide their finals thoughts and main points on the management of patients with Hodgkin lymphoma.

In the future, Pinter-Brown hopes, chemotherapy will no longer be necessary in the management of Hodgkin lymphoma. She hopes that through the utilization of immunotherapy and novel combinations the side effects associated with chemotherapy can be avoided.

The treatment of Hodgkin lymphoma has majorly impacted the care of patients with other types of cancer, Friedberg believes. Furthermore, he adds, the high cure rate in this disease represents one of the biggest victories in medical and radiation oncology. Moving forward, interim imaging and the frontline administration of novel agents will continue to enhance the treatment paradigm. Given this success, a new course has been forged in survivorship care, as patients are now living for decades after their initial diagnosis, Hamlin notes.

The goal in Hodgkin lymphoma is to cure patients with the least amount of treatment, Moskowitz adds. However, if a patient progresses on all standard treatments it is appropriate to administer the older Mustargen Oncovin Procarbazine Prednisone (MOPP) chemotherapy regimen.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Alessandra Ferrajoli, MD
Dipti Patel-Donnelly, MD, Johns Hopkins
Jasmin M. Zain, MD
Andrew Ip, MD
Sagar S. Patel, MD